MBRX
MBRX
NASDAQ · Biotechnology

Moleculin Biotech Inc

$2.29
+0.05 (+2.23%)
Financial Highlights (FY 2025)
Revenue
2.53M
Net Income
-604,093
Gross Margin
49.0%
Profit Margin
-23.9%
Rev Growth
-6.1%
D/E Ratio
0.51
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 49.0% 49.0% 49.0%
Operating Margin -25.0% -25.3% -26.7%
Profit Margin -23.9% -23.9% -24.2%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 2.53M 2.25M 2.34M
Gross Profit 1.24M 1.10M 1.15M
Operating Income -632,208 -569,192 -624,707
Net Income -604,093 -536,841 -566,432
Gross Margin 49.0% 49.0% 49.0%
Operating Margin -25.0% -25.3% -26.7%
Profit Margin -23.9% -23.9% -24.2%
Rev Growth -6.1% -2.1% -7.6%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 4.62M 5.29M 5.47M
Total Equity 9.01M 8.31M 8.07M
D/E Ratio 0.51 0.64 0.68
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -828,287 -680,626 -721,197
Free Cash Flow -326,986 -310,260 -424,378